Triazole N-linked carbamoyl cyclohexyl acids as LPA antagonists
US-10662172-B2 · May 26, 2020 · US
Carbamoyloxymethyl triazole cyclohexyl acids as LPA antagonists
US11007180B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11007180-B2 |
| Application number | US-202016732387-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jan 2, 2020 |
| Priority date | Jun 21, 2016 |
| Publication date | May 18, 2021 |
| Grant date | May 18, 2021 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention provides compounds of Formula (I): or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.
First claim
Opening claim text (preview).
What is claimed is: 1. A compound of Formula (XI):
Assignees
Inventors
Classifications
containing three or more hetero rings · CPC title
- C07D401/04Primary
directly linked by a ring-member-to-ring-member bond · CPC title
with aryl radicals directly attached to ring atoms · CPC title
Immunosuppressants, e.g. drugs for graft rejection · CPC title
specific for leukemia · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11007180B2 cover?
- The present invention provides compounds of Formula (I): or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.
- Who is the assignee on this patent?
- Bristol Myers Squibb Co
- What technology area does this patent fall under?
- Primary CPC classification C07D401/04. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue May 18 2021 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 5 related publications on this page (citations in our corpus or others sharing the same primary CPC).